Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator

Su, Fu-Min; Beaumier, Paul L.; Axworthy, Donald B.; Atcher, Robert W.; Fritzberg, Alan R.

doi:10.1016/j.nucmedbio.2005.06.009

Cited by 47 publications

(44 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of radioactive biotin derivatives for selective localization on antibody-streptavidin conjugates (24,25) or noncovalent biotinylated antibody-streptavidin complexes, termed 3-step pretargeting (26). 2.…”

Section: Pretargetingmentioning

confidence: 99%

Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends

Steiner

Neri²

2011

Clinical Cancer Research

147

129

View full text Add to dashboard Cite

When delivered at a sufficient dose and dose rate to a neoplastic mass, radiation can kill tumor cells. Because cancer frequently presents as a disseminated disease, it is imperative to deliver cytotoxic radiation not only to the primary tumor but also to distant metastases, while reducing exposure of healthy organs as much as possible. Monoclonal antibodies and their fragments, labeled with therapeutic radionuclides, have been used for many years in the development of anticancer strategies, with the aim of concentrating radioactivity at the tumor site and sparing normal tissues. This review surveys important milestones in the development and clinical implementation of radioimmunotherapy and critically examines new trends for the antibody-mediated targeted delivery of radionuclides to sites of cancer.

show abstract

Section: Pretargetingmentioning

confidence: 99%

Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends

Steiner

Neri²

2011

Clinical Cancer Research

147

129

View full text Add to dashboard Cite

show abstract

“…Bismuth compounds have been extensively studied in the respect of their biological activity [17,[20][21][22][23][24][25][26][27][28]. In a large number of papers their antibacterial properties have been reported [17,20,21,[23][24][25][26][27].…”

Section: Introductionmentioning

confidence: 99%

“…In a large number of papers their antibacterial properties have been reported [17,20,21,[23][24][25][26][27]. Therefore bismuth compounds are applied in medicine, e.g.…”

Section: Introductionmentioning

confidence: 99%

Influence of pH and type of counterion on the formation of bismuth(III) complexes with tropolonato and 5-methyltropolonato ligands: Synthesis, structure, spectroscopic characterization and calculation studies

Łyczko

Lyczko

Woźniak

et al. 2015

Inorganica Chimica Acta

View full text Add to dashboard Cite

“…Su et al examined the potential of antibody pre-targeting therapy with 212 Pb using an NR-LU-10 antibody-streptavidin conjugate administrated first followed by an N-acetyl-galactosamie-biotin clearing agent [37]. The pre-targeting of 212 Pb/ 212 Bi provided good tumor uptake, tumor-to-blood ratio and normal non-target tissue/blood ratio with the exception of kidney, the primary biological deposition site for Bi(III).…”

Section: Molecular Delivery Platform Of 212pbmentioning

confidence: 99%

Application of <sup>212</sup>Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation

Yong¹,

Brechbiel

2015

medicalScience

View full text Add to dashboard Cite

Targeted α-particle therapy (TAT), in which an α-particle emitting radionuclide is specifically directed to a biological target, is gaining more attention to treat cancers as new targets are validated. Bio-vectors such as monoclonal antibodies are able to selectively transport α-particles to destroy targeted cancer cells. TAT has the potential for an improved therapeutic ratio over β-particle targeted conjugate therapy. The short path length and the intense ionization path generated render α-emitters suitable for treatment and management of minimal disease such as micrometastases or residual tumor after surgical debulking. 212Pb is the longer-lived parent radionuclide of 212Bi and serves as an in vivo generator of 212Bi. 212Pb has demonstrated significant utility in both in vitro and in vivo models. Recent evaluation of 212Pb-TCMC-trastuzumab in a Phase I clinical trial has demonstrated the feasibility of 212Pb in TAT for the treatment of ovarian cancer patients. This review highlights progress in radionuclide production, radiolabeling chemistry, molecular mechanisms, and application of 212Pb to targeted pre-clinical and clinical radiation therapy for the management and treatment of cancer.

show abstract

Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator

Cited by 47 publications

References 5 publications

Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends

Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends

Influence of pH and type of counterion on the formation of bismuth(III) complexes with tropolonato and 5-methyltropolonato ligands: Synthesis, structure, spectroscopic characterization and calculation studies

Application of <sup>212</sup>Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation

Contact Info

Product

Resources

About